The FDA has approved an application to market the emergency contraceptive Plan B One-Step for use without a prescription by women 15 years of age and older.
The US Food and Drug Administration (FDA) announced that it has approved an application submitted by Teva Women’s Health to market the emergency contraceptive Plan B One-Step (levonorgestrel) for use without a prescription by women 15 years of age and older. In December 2011, Teva had submitted an application to make Plan B One-Step available over the counter (OTC) to all girls of reproductive age, however at that time the FDA did not approve the application.
This approval is based on an actual use study and label comprehension data submitted by Teva showing that women age 15 and older understood that the product was not for routine use and would not protect them against sexually transmitted diseases. The FDA stated that “Plan B One-Step will be packaged with a product code prompting a cashier to request and verify the customer’s age. A customer who cannot provide age verification will not be able to purchase the product.” To prevent theft, a security tag will be placed on all product cartons of Plan B One-Step.
“Research has shown that access to emergency contraceptive products has the potential to further decrease the rate of unintended pregnancies in the United States,” said FDA Commissioner Margaret A. Hamburg, MD. “The data reviewed by the agency demonstrated that women 15 years of age and older were able to understand how Plan B One-Step works, how to use it properly, and that it does not prevent the transmission of a sexually transmitted disease.”
Besides Plan B One-Step, there are currently two other emergency contraceptive drugs available in the United States: Plan B and ella. Plan B is a prescription contraceptive that is available from generic manufacturers for women over the age of 17. It is comprised of two doses of levonorgestrel (.75 mg in each tablet) taken 12 hours apart. Ella (ulipristal) also requires a prescription, and prevents pregnancy when taken orally within 5 days after unprotected sexual intercourse.
Plan B One-Step will not stop a pregnancy when a woman is already pregnant, and there is no medical evidence that the product will harm a developing fetus.
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
Inactivated COVID-19 vaccines in pregnancy: No impact on neonatal outcome, study finds
November 28th 2023A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Smart Women’s Choice faces federal court order to halt unlawful contraceptive distribution
November 16th 2023The US District Court for the District of Arizona issued an order against Arizona-based company Smart Women’s Choice, Inc, following a complaint by the US Department of Justice, alleging the distribution of unapproved new drugs in violation of the Federal Food, Drug, and Cosmetic Act.
Read More
Model for predicting cesarean delivery in gestational diabetes
November 15th 2023A recent study unveils a pragmatic model, incorporating factors such as insulin requirements, preeclampsia, and maternal age, to effectively predict primary cesarean delivery risk in pregnancies complicated by gestational diabetes mellitus.
Read More